tbuckley/cabot-search huggingface dataset:
Abstract 18977: Improving Self-care for Diabetes Affects Heart Failure Outcomes in Persons With Heart Failure and Concomitant Diabetes
Authors: Sandra B Dunbar, Melinda Higgins, Carolyn Reilly, Javed Butler
Journal: Circulation (2017)

Introduction: Persons with heart failure (HF) and diabetes mellitus (DM) have great variability in their self-care activities which may conflict or compete. An integrated HF-DM self-care intervention yielded positive effects on HF quality of life (QOL), improved physical activity and improved physical functioning (PF). A greater understanding of the predictors of PF and QOL and relationship to self-care behaviors may improve precision of intervention approaches. Purpose: To identify the demographic, clinical and behavioral factors associated with positive change in PF and QOL in response to the intervention. Methods: Methods: HF-DM participants (n=134), 57.4 ± 11 years, 66% men, 69% African American, were randomized to usual care (UC) or intervention (INT) with assessments at baseline (BL), and 6 months (M). Intervention included education/counseling about HF-DM self-care (diet, medications, self-monitoring, symptoms, and enhanced emphasis on physical activity), home visit after hospital discharge, and mo...
Inhibition of TNF-alpha by anti-inflammatory drug Etanercept is radioprotective for liver
Authors: Ming Zhang, xianying xing, Theodore Lawrence
Journal: Cancer Research (2007)

3123   Effectiveness of radiotherapy for cancer depends on the maximal radiation dose that can be tolerated by normal tissue. In particular, radiation-induced liver toxicity becomes a major limitation during radiation treatment for liver tumors. We previously demonstrated that ionizing radiation causes liver function damage as a result of apoptosis mediated by TNF-alpha elevation in the liver. In this study, we tested the potential of using Etanercept (EnbrelÂ®), a TNF-alpha blocker that is effective in treating rheumatoid arthritis, as protective agent during liver radiation. C57BL/6 mice were treated with Etanercept (i.p., the dose range of 0.4 to 6.4 mg/kg) at the time before (24 or 2 h) or immediately after (0 h) a single dose of radiation with 4, 12.5, or 25 Gy. Liver function was assessed by serum AST/ALT activities at 2 h post radiation treatment and was further correlated with liver apoptosis measurements using TUNEL staining and caspase-3 western blotting. Etanercept was effective from the dose of 1.6 mg/kg when it was administered at 2 h prior to or immediately after 12.5 Gy of radiation, resulting in ~70% or ~60% increases of serum ALT relative to an increase of ~350% in control mice. This protection was minor when Etanercept (1.6 mg/kg) was used at 24 h before radiation or Etanercept at lower dose (0.4 or 0.8 mg/kg) was used. Consistently, radiation-induced liver apoptosis as quantified by TUNEL staining was significantly lower when mice were pre-treated with 1.6 mg/kg of Etanercept (~3.5-, ~4.5-, and ~5.0-fold) compared to control mice (~5.0-, ~6.3-, and ~8.2-fold) at the radiation dose of 4, 12.5, and 25 Gy, respectively. This protective effect was dramatically improved by the use of higher Etanercept dose (6.4 mg/kg), which produced only ~1.5-, ~3.0-, and ~3.5-fold induction of TUNEL positive cells at respective radiation doses, and was further confirmed by the decreasing of caspase-3 cleavage in western blot analysis. Etanercept-mediated liver protection against fractionated radiation was also investigated. We conclude that specific inhibition of TNF-alpha by Etanercept is radioprotective for mice liver and is a potentially effective radioprotector during liver radiotherapy.
Abstract 11776: Lower Body Mass Index is a Risk Factor of Blunted Response to β-Blocker Therapy Using Carvedilol: Insights From J-CHF Study
Authors: Yuji Nagatomo, Tsutomu Yoshikawa, Hiroshi Okamoto, Akira Kitabatake, Masatsugu Hori
Journal: Circulation (2017)

Introduction: Cardiac cachexia is a strong predictor of a poor clinical outcome in patients with heart failure (HF), whereas the prognosis of obese HF patients is more favorable compared with lean ...
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Authors: Bradley D Hunter, Caron A Jacobson
Journal: JNCI Journal of the National Cancer Institute (2019)

Abstract Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new form of immunotherapy for the treatment of hematologic malignancies. The two primary toxicities associated with CAR T-cell therapy include cytokine-release syndrome and neurotoxicity. Cytokine-release syndrome is generally self-limited but high-grade toxicities like hypotension and hypoxemia can be managed with agents that block the effects of IL-6, like tocilizumab, and/or corticosteroids. Although CAR T-cell therapy–associated neurotoxicity is a well-described clinical phenomenon, its pathophysiology remains inadequately understood; treatments and preventive strategies remain elusive. Animal models and clinical trial experience suggest the centrality of monocytes, endothelial dysfunction, and the blood-brain barrier in the development of CAR T-cell–associated neurotoxicity. Here we report what is known from preclinical models, clinical trials, and histopathologic studies regarding the pathophysiology of neurotoxicity, predictors of its incidence, and potential targets for the treatment and prevention of neurotoxicity.
Fusion process and fusion efficiency is essential to optimal antitumor immunity
Authors: Yutaka Enomoto, Shigeo Koido, Chunlei Liu, Jianlin Gong
Journal: Cancer Research (2005)

3444  The fusion of dendritic cells (DC) and tumor cells is an effective approach to the design of vaccines in cancer immunotherapy. However, question has been raised whether the fusion process is essential for the potency of DC/tumor fusion cells since most DC-based vaccines can induce antitumor immune response. In the present study, we fused DC with MC38/MUC1 tumor cells and examined the relationship between fusion process, fusion efficiency and antitumor immunity. The fusion efficiency was determined by dual expression of MHC class II as DC marker and MUC1 as tumor marker at multiple time points. On day 1, only 3.81% cells expressed MUC1 and MHC class II. The double positive cells increased to 10.2% on day 4 and 36.2% on day 7 culture. In contrast, only 3.96% of cells were double positive for MHC class II and MUC1 when DC were mixed with tumor cells without PEG and cultured for 7 days. These results indicate that fusion of DC and tumor cells using PEG as a fusogen is a dynamic and evolving process and that short-term culture of fusion cell products promotes the fusion efficiency. In addition, fusion process is essential for the optimal expression of both tumor antigens and DC markers. To determine the relationship between fusion efficiency and immune response, groups of MUC1 transgenic mice were immunized with 5 × 105 cells obtained from day 1, 4 and 7 fusion products. Immunization of mice with day 1, 4 and 7 day fusion products provided 20%, 70% and 100% protection, respectively, against challenge with 5 × 105 MC38/MUC1 tumor cells. Impaired antitumor immunity was observed in mice immunized with DC mixed with tumor cells. Eight out of 9 mice immunized with DC mixed with tumor cells on day 7 culture developed tumors. Similar results were obtained in CTL assay. Immunization of mice with fusion products on day 7 culture resulted in the induction of the highest CTL activity against MC38/MUC1 tumor cells. Taken together, these results indicate that fusion efficiency is closely correlated with antitumor immunity and that fusion process is indispensable for the optimal antitumor immunity.
The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages
Authors: Julie Schulthess, Sumeet Pandey, Melania Capitani, Kevin C. Rue-Albrecht, Isabelle Arnold, Fanny Franchini, Agnieszka Chomka, Nicholas E. Ilott, Daniel G.W. Johnston, Elisabete Pires, James McCullagh, Stephen N. Sansom, Carolina V. Arancibia-Cárcamo, Holm H. Uhlig, Fiona Powrie
Journal: Immunity (2019)
Can India lead the way in neglected diseases innovation?
Authors: Zakir Thomas, Gautam Kumar Saha, Kappoori Madhavan Gopakumar, Nirmal Kumar Ganguly
Journal: BMJ (2019)

<b>Nirmal Kumar Ganguly and colleagues</b> call for a comprehensive policy for neglected diseases research in India to foster innovation in drugs, diagnostics, and vaccines, critical for evolving needs of elimination programmes
<i>KRAS</i> amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA).
Authors: Russell Madison, Joseph Chao, Jeffrey S. Ross, Vincent A. Miller, Siraj Mahamed Ali, Alexa Betzig Schrock, Samuel Jacob Klempner
Journal: Journal of Clinical Oncology (2019)

70 Background: KRAS mutations are common oncogenic events across cancers, but effective RAS-directed therapies are lacking. However, recent studies support use of PD-1 blockade in most subsets of lung cancer with KRAS short variant mutations (KRAS SV ) (PMID: 28039262), and preclinical data supports combined MEK and SHP2 inhibition in KRAS amplified ( KRAS a ) GEA (PMID: 30093730). We sought to explore the landscape of KRAS altered GEA and compare genomic profiles of KRAS-altered and KRAS wild-type (WT) cases for biomarkers of response to targeted therapies and immune checkpoint inhibitors. Methods: 6,667 tissue specimens from patients with advanced GEA were assayed using hybrid capture-based comprehensive genomic profiling. Tumor mutational burden (TMB) was determined on up to 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 95 or 114 loci. Descriptive statistics were used to compare among subgroups. Results: KRAS SV and KRAS a were identified in 11% and 5.8% of gastric adenocarcinoma (GA), respectively, and in 7.2% and 17% of esophageal adenocarcinoma (EA), respectively. KRAS a and KRAS SV were nearly mutually exclusive, co-occurring in only 4.4% of KRAS altered cases. ERBB2 alterations were less common in KRAS SV and KRAS a GEA (both 9%) as compared with KRAS WT GEA (19%) (p = 1.9E-16). EGFR a was less common in KRAS SV versus KRAS a GEA (1.9% vs. 9.3%, p = 2.6E-8), whereas PIK3CA SV was more common in KRAS SV versus KRAS a (16% vs 5.0%, p = 1.5E-11). Median TMB for all groups was similar; however, KRAS SV GEA had a higher mean TMB (9.7 mut/Mb) as compared to KRAS a (5.1 mut/Mb, p = 5.0E-12) and KRAS WT cases (5.8 mut/Mb, p = 2.2E-07). KRAS codon 12/13 accounted for &gt; 80% of predicted pathogenic mutations. MSI-high was also more prevalent in KRAS SV (11.4%) versus KRAS a (0.9%, p = 4.8E-15) and KRAS WT GEA (3.0%, p = 1.8E-25). MSI-high KRAS SV GEA was associated with older patient age (median 72 years) and with high TMB (median 40.9 mut/mb). Conclusions: GA was enriched for KRAS mutation whereas EA was enriched for KRAS amplification. KRAS WT versus KRAS SV versus KRAS a each presented distinct genomic profiles. KRAS a in the absence of KRAS mutation exists in 11% of GEA and warrants further exploration to inform combination treatment strategies.
The Evolving Story of Triglycerides and Coronary Heart Disease Risk
Authors: Ann Marie Navar
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nasal peanut+ CpG immunotherapy enhances peanut‐specific <scp>IFN</scp>‐γ in Th2 cells and <scp>IL</scp>‐10 in non‐Th2 cells in mice
Authors: Brandi T. Johnson‐Weaver, Gregory D. Sempowski, Herman F. Staats
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
In premenopausal women with recurrent cystitis, increasing water intake for 12 months reduced recurrence
Authors: Roger R. Dmochowski
Journal: Annals of Internal Medicine (2019)

Source Citation Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178:1509-15. 30285042
Impact of Incomplete Cycles and Dose Attenuation of Rituximab-Bendamustine on Survival Outcomes in Low-Grade Non-Hodgkin Lymphomas
Authors: Yunxin Chen, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Shin-Yeu Ong, Kit Yan Loh, Allan Zhi Kai Goh, Yeow Tee Goh, Yuh Shan Lee
Journal: Blood (2018)
Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis
Authors: Akira Honda, Atsushi Tanaka, Tetsuji Kaneko, Atsumasa Komori, Masanori Abe, Mie Inao, Tadashi Namisaki, Naoaki Hashimoto, Kazuhito Kawata, Atsushi Takahashi, Masashi Ninomiya, Jong‐Hon Kang, Mie Arakawa, Satoshi Yamagiwa, Satoru Joshita, Takeji Umemura, Ken Sato, Akira Kaneko, Kentaro Kikuchi, Jun Itakura, Takako Nomura, Keisuke Kakisaka, Hideki Fujii, Norifumi Kawada, Yasuhiro Takikawa, Tsutomu Masaki, Hiromasa Ohira, Satoshi Mochida, Hitoshi Yoshiji, Satoshi Iimuro, Yasushi Matsuzaki, Hajime Takikawa
Journal: Hepatology (2019)

In Japan, bezafibrate (BF) is a second-line agent for primary biliary cholangitis (PBC) that is refractory to ursodeoxycholic acid (UDCA) treatment. From a retrospective cohort (n = 873) from the Japan PBC Study Group, we enrolled 118 patients who had received UDCA monotherapy for at least 1 year followed by combination therapy with UDCA+BF for at least 1 year. GLOBE and UK-PBC scores after UDCA monotherapy (i.e., immediately before UDCA+BF combination therapy) were compared with those after 1 year of UDCA+BF combination therapy. The real outcomes of enrolled patients estimated by Kaplan-Meier analysis were compared with the predicted outcomes calculated using GLOBE and UK-PBC scores. In addition, the hazard ratio of BF treatment was calculated using propensity score analysis. The mean GLOBE score before the combination therapy was 0.504 ± 0.080, which improved significantly to 0.115 ± 0.085 (P < 0.0001) after 1 year of combination therapy. The real liver transplant-free survival of enrolled patients was significantly better than that predicted by GLOBE score before introducing BF. Combination therapy did not significantly improve the real rates of liver transplantation or liver-related death compared with those predicted by UK-PBC risk score before introducing BF, but the predicted risk was significantly reduced by the addition of BF (P < 0.0001). Cox regression analysis with inverse probability of treatment weighting showed that the addition of BF significantly reduced the hazard of liver transplant or liver-related death in patients who, after 1 year of UDCA monotherapy, had normal serum bilirubin (adjusted hazard ratio 0.09, 95% confidence interval 0.01-0.60, P = 0.013). Conclusion: Addition of BF to UDCA monotherapy improves not only GLOBE and UK-PBC scores but also the long-term prognosis of PBC patients, especially those with early-stage PBC.
Supervised Injection Facilities
Authors: Lawrence O. Gostin, James G. Hodge, Chelsea L. Gulinson
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image
Authors: Young-Sil An, Joon-Kee Yoon, Su Jin Lee, Eugene Jeong, Il-hyun Kim
Journal: Clinical Nuclear Medicine (2019)

F-FP-CIT PET is a useful modality for imaging dopamine transporters. It has excellent resolution compared with I-beta-CIT SPECT and is widely used clinically for the evaluation of Parkinson disease. In general, the main focus of F-FP-CIT PET imaging is the basal ganglia, and it is important to observe whether F-FP-CIT uptake is normal in the putamen and caudate nuclei. However, abnormal findings may be seen in other brain regions besides the basal ganglia. Here, we present a case of anaplastic oligodendroglioma, a high-grade tumor, which was found as an incidental photopenic lesion on F-FP-CIT PET/CT.
Abstract 18736: Human Adipose Tissue Inflammation Decreases CD271-Positive Adipose Derived Stem Cells and Deteriorates Therapeutic Angiogenesis of Cell Transplantation for Critical Limb Ischemia
Authors: Oto Inoue, Soichiro Usui, Shin-ichiro Takashima, Takuto Hamaoka, Teppei Kitano, Hiroshi Ootsuji, Ayano Nomura, Kenji Iino, Takeshi Kato, Hisayoshi Murai, Hiroshi Furusho, Hirohumi Takemura, Shuichi Kaneko, Masayuki Takamura
Journal: Circulation (2016)

Introduction: Adipose derived stem cells (ADSCs) have been tested in cardiovascular diseases (CVD). However, CVD patients often accompany adipose tissue (AT) inflammation triggered by impaired angi...
Spending on locums has fallen 44% since introduction of wage cap
Authors: Tom Moberly
Journal: BMJ (2019)

Spending on locums by NHS trusts has fallen by 44% since the introduction of wage caps and other measures aimed at controlling the rising cost of agency staff.

The service sought to introduce measures to control spending on locums after paying £3bn (€3.4bn; $3.9bn) for agency staff in 2014-15. In November 2015 a cap on the …
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
Authors: Krzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Andrew J. Carroll, Christopher J. Walker, Deedra Nicolet, James S. Blachly, Marius Bill, Dimitrios Papaioannou, Eunice S. Wang, Geoffrey L. Uy, Jonathan E. Kolitz, Bayard L. Powell, William Blum, Richard M. Stone, John C. Byrd, Clara D. Bloomfield
Journal: Leukemia (2019)
LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway
Authors: Yin-Li Zheng, Lei Li, Yong-Xun Jia, Bao-Zhu Zhang, Jiang-Chao Li, Ying-Hui Zhu, Meng-Qing Li, Jiao-Zi He, Ting-Ting Zeng, Xiao-Jiao Ban, Yun-Fei Yuan, Yan Li, Xin-Yuan Guan
Journal: Theranostics (2019)

Background and Aims: Cancer cells prefer aerobic glycolysis to maintain growth advantages, but the role of long non-coding RNAs (lncRNAs) in glycometabolism still remains unclear. Here we identified one cytoplasmic lncRNA LINC01554 as a significantly downregulated lncRNA in hepatocellular carcinoma (HCC) and aimed to investigate its role in cellular glucose metabolism in the development and progression of HCC. Methods: Quantitative real-time PCR was used to determine the expression level of LINC01554. Downregulation of LINC01554 by miR-365a at transcriptional level was assessed by luciferase reporter assay. Subcellular fractionation assay and RNA fluorescence in situ hybridization were performed to detect the subcellular localization of LINC01554. RNA pull-down assay, mass spectrometry, and RNA immunoprecipitation assay were used to identify the underlying molecular mechanisms. The tumor-suppressive function of LINC01554 was determined by both in vitro assay and nude mice xenograft model. Results: LINC01554 was frequently downregulated in HCC, which was significantly associated with tumor invasion (P = 0.005), tumor size (P = 0.041), tumor staging (P = 0.023) and shorter survival (P = 0.035) of HCC patients. Luciferase reporter assay unraveled that LINC01554 was negatively regulated by miR-365a. Subcellular fractionation assay and RNA FISH revealed the cytoplasmic predominance of LINC01554 in MIHA cells and HCC clinical samples. Ectopic expression of LINC01554 inhibited HCC cell growth, colony formation in soft agar, foci formation, and tumor formation in nude mice. LINC01554 promoted the ubiquitin-mediated degradation of PKM2 and inhibited Akt/mTOR signaling pathway to abolish aerobic glycolysis in HCC cells. Further study found that LINC01554-knockout could effectively reverse the tumor-suppressive effect of LINC01554. Conclusions: Our results identify LINC01554 as a novel tumor suppressor in HCC and unravel its underlying molecular mechanism in reprogramming cellular glucose metabolism. LINC01554 could possibly serve as a novel prognostic biomarker and provide the rationale for HCC therapy.
Antibiotic‐Free Cationic Dendritic Hydrogels as Surgical‐Site‐Infection‐Inhibiting Coatings
Authors: Oliver C. J. Andrén, Tobias Ingverud, Daniel Hult, Joakim Håkansson, Yalda Bogestål, Josefin S. Caous, Kristina Blom, Yuning Zhang, Therese Andersson, Emma Pedersen, Camilla Björn, Peter Löwenhielm, Michael Malkoch
Journal: Advanced Healthcare Materials (2019)

Abstract A non‐toxic hydrolytically fast‐degradable antibacterial hydrogel is herein presented to preemptively treat surgical site infections during the first crucial 24 h period without relying on conventional antibiotics. The approach capitalizes on a two‐component system that form antibacterial hydrogels within 1 min and consist of i) an amine functional linear‐dendritic hybrid based on linear poly(ethylene glycol) and dendritic 2,2‐bis(hydroxymethyl)propionic acid, and ii) a di‐ N ‐hydroxysuccinimide functional poly(ethylene glycol) cross‐linker. Broad spectrum antibacterial effect is achieved by multivalent representation of catatonically charged β‐alanine on the dendritic periphery of the linear dendritic component. The hydrogels can be applied readily in an in vivo setting using a two‐component syringe delivery system and the mechanical properties can accurately be tuned in the range equivalent to fat tissue and cartilage ( G′ = 0.5–8 kPa). The antibacterial effect is demonstrated both in vitro toward a range of relevant bacterial strains and in an in vivo mouse model of surgical site infection.
A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service
Authors: Giuseppina Abignano, Nafisa Fadl, Mira Merashli, Claire Vandevelde, Jane Freeston, Dennis McGonagle, Helena Marzo-Ortega
Journal: Journal of the American Academy of Dermatology (2019)